ERBB2 and breast carcinoma: The amplification of the Human Epidermal Growth Factor Receptor-2, ErbB2 (HER2), identified in 15 to 20% of breast cancers (BCs), is a factor of tumor aggressiveness that has been associated with more frequent relapses and poor survival rates since a long time [1].